Breaking News Instant updates and real-time market news.

PCRX

Pacira

$35.40

-4.45 (-11.17%)

, HRTX

Heron Therapeutics

$39.55

8.85 (28.83%)

15:42
06/21/18
06/21
15:42
06/21/18
15:42

Pacira's Exparel may face greater threat from Heron drug, says BMO Capital

BMO Capital analyst Gary Nachman said the newly released Phase 2b data for Heron Therapeutics' (HRTX) HTX-011 in post-surgical pain support a "very solid profile" for the drug, which he thinks will eventually likely be a "viable competitor" to Pacira's (PCRX) Exparel. Given the new data, a more cautious long-term outlook for Exparel may be warranted, contends Nachman, who keeps a Market Perform rating on Pacira shares. In late day trading, Heron shares are up 29% to $39.70, while Pacira has fallen 12% to $34.98.

PCRX

Pacira

$35.40

-4.45 (-11.17%)

HRTX

Heron Therapeutics

$39.55

8.85 (28.83%)

  • 21

    Jun

  • 26

    Jun

  • 27

    Jun

PCRX Pacira
$35.40

-4.45 (-11.17%)

04/23/18
CANT
04/23/18
NO CHANGE
Target $40
CANT
Overweight
Doctor call supports Cantor's positive thesis on Heron Therapeutics
After hosting a conference call with two physicians to better understand how HTX-011 will fit into the post-operative pain market, Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Heron Therapeutics (HRTX) with a $40 price target. Both physicians do not see Pacira Pharmaceuticals' (PCRX) Exparel being used anymore if HTX-011 is approved, Chen tells investors in a research note. The doctors believe that HTX-011 is a better drug that is likely to be priced lower than Exparel, the analyst points out. Chen says the call supports her positive thesis on Heron.
05/03/18
HCWC
05/03/18
NO CHANGE
Target $48
HCWC
Buy
Pacira being conservative with no guidance raise, says H.C. Wainwright
Pacira Pharmaceuticals this morning posted solid Q1 Exparel sales of $74M, just ahead of the Street's $73.1M estimate and up over 9% year-on-year, H.C. Wainwright analyst Oren Livnat tells investors in a research note. He found it important that management highlighted strong intra-quarter growth trends with 6% growth in January accelerating to 15% in March. The analyst believes, however, that investors are concerned with no Exparel guidance increase and "confusing potential near-term Exparel reimbursement developments, or lack thereof." Livnat believes management is being conservative with the outlook and reiterates a Buy rating on Pacira with a $48 price target. The stock in midday trading is down 4% to $32.95.
05/04/18
JMPS
05/04/18
NO CHANGE
Target $56
JMPS
Outperform
Pacira price target lowered to $56 from $65 at JMP Securities
JMP Securities analyst Donald Ellis noted that Pacira Pharmaceuticals reported Q1 earnings that were in-line with consensus and the company reiterated FY18 Exparel sales guidance. He lowered his price target on Pacira to $56 from $65 to account for his updated peer PEG ratios. Ellis maintains an Outperform rating on Pacira, stating that he believes the combination of the DPS partnership, scrutiny against opioids and recent approvals are contributing to the acceleration in Exparel sales.
06/06/18
JEFF
06/06/18
NO CHANGE
Target $49
JEFF
Buy
Pacira sales inflection may 'finally be underway,' says Jefferies
After hosting an investor dinner with Pacira Pharmaceuticals (PCRX) CEO Dave Stack, Jefferies analyst David Steinberg believes a "meaningful sales inflection for Exparel may finally be underway." Management is increasingly confident that an Exparel sales inflection, driven by the Johnson & Johnson (JNJ) partnership and expanded nerve block indication, is underway, Steinberg tells investors in a research note. Further, he believes a "potentially significant" Exparel rest-of-work partnership is likely to be announced prior to the end of 2018. The analyst keeps a Buy rating on Pacira Pharmaceuticals with a $49 price target.
HRTX Heron Therapeutics
$39.55

8.85 (28.83%)

06/21/18
EVER
06/21/18
NO CHANGE
Target $80
EVER
Outperform
Heron Therapeutics price target raised to $80 from $56 at Evercore ISI
Evercore ISI analyst Josh Schimmer raised his price target on Heron Therapeutics to $80 from $56 after the company announced positive topline results from two Phase 2b studies of HTX-011.
06/21/18
06/21/18
NO CHANGE
Target $80

Outperform
Heron Therapeutics price target raised to $80 on positive HTX-011 results at Evercore ISI
As previously reported, Evercore ISI analyst Josh Schimmer raised his price target for Heron Therapeutics to $80 from $56 after the company reported data from its two Phase 2b studies of HTX-011 for prevention of post-op pain following total knee arthroplasty and breast augmentation. The analyst notes that these were primarily for procuring a broad post-surgical label based on the highly compelling Phase 3 studies of the product in bunionectomy and hernia repair by demonstrating safety and predictable PK. HTX-011 not only demonstrated the required safety and PK profile to support a broad label, but the results showed clear clinical benefit over both placebo and bupivacaine, Schimmer adds. The analyst reiterates an Outperform rating on the shares.
06/21/18
CANT
06/21/18
NO CHANGE
Target $40
CANT
Overweight
Cantor has $59 per share 'bull case scenario' for Heron Therapeutics
Cantor Fitzgerald analyst Louise Chen says the positive data announced this morning by Heron Therapeutics will support the new drug application filing for HTX-011 and expand the commercial opportunity for the drug. The analyst continues to believe that the peak sales potential for HTX-011 is being underappreciated. She has a $40 price target on the shares with a $59 "bull case scenario." Chen keeps an Overweight rating on Heron Therapeutics. The stock in morning trading is up 30% to $39.82.
06/21/18
NEED
06/21/18
NO CHANGE
Target $66
NEED
Buy
Heron Therapeutics price target raised to $66 from $42 at Needham
Needham analyst Serge Belanger raised his price target on Heron Therapeutics to $66 after the company announced positive topline results from two Phase 2b studies of HTX-011 for prevention of post-op pain following total knee arthroplasty and breast augmentation.

TODAY'S FREE FLY STORIES

SEED

Origin Agritech

$5.84

0.03 (0.52%)

10:01
10/17/18
10/17
10:01
10/17/18
10:01
Hot Stocks
Origin Agritech announces strategic agreement with Longhan Investment »

Origin Agritech announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBR

Centrais Electricas

$5.42

-0.43 (-7.35%)

10:00
10/17/18
10/17
10:00
10/17/18
10:00
Hot Stocks
Centrais Electricas falls -8.0% »

Centrais Electricas is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVIA

Covia

$6.75

-0.83 (-10.95%)

10:00
10/17/18
10/17
10:00
10/17/18
10:00
Hot Stocks
Covia falls -11.1% »

Covia is down -11.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMS

Fresenius Medical

$41.00

-8.865 (-17.78%)

10:00
10/17/18
10/17
10:00
10/17/18
10:00
Hot Stocks
Fresenius Medical falls -17.7% »

Fresenius Medical is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSC

Global Geoscience

$26.00

(0.00%)

10:00
10/17/18
10/17
10:00
10/17/18
10:00
Hot Stocks
Global Geoscience rises 5.6% »

Global Geoscience is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISCB

Discovery Inc.

$34.00

(0.00%)

10:00
10/17/18
10/17
10:00
10/17/18
10:00
Hot Stocks
Breaking Hot Stocks news story on Discovery Inc. »

Discovery Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRAM

Grana y Montero

$2.95

(0.00%)

10:00
10/17/18
10/17
10:00
10/17/18
10:00
Hot Stocks
Grana y Montero rises 6.6% »

Grana y Montero is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WGO

Winnebago

$36.50

4.72 (14.85%)

10:00
10/17/18
10/17
10:00
10/17/18
10:00
Hot Stocks
Winnebago rises 14.7% »

Winnebago is up 14.7%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

TLRY

Tilray

$148.37

-9.77 (-6.18%)

09:58
10/17/18
10/17
09:58
10/17/18
09:58
Hot Stocks
Tilray CEO says contacted by Fortune 500 pharmaceutical, CPG companies »

Tilray CEO Brendan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNTTF

CannTrust Holdings

$0.00

(0.00%)

, TLRY

Tilray

$148.37

-9.77 (-6.18%)

09:58
10/17/18
10/17
09:58
10/17/18
09:58
Periodicals
Congressman issues 'Blueprint to Legalize Marijuana' in 2019, Forbes reports »

Democratic congressman…

CNTTF

CannTrust Holdings

$0.00

(0.00%)

TLRY

Tilray

$148.37

-9.77 (-6.18%)

CRON

Cronos Group

$10.27

-1.23 (-10.70%)

CANN

General Cannabis

$0.00

(0.00%)

ACBFF

Aurora Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$4.12

-0.38 (-8.44%)

CGC

Canopy Growth

$49.33

-3.63 (-6.85%)

CVSI

CV Sciences

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 14

    Nov

  • 29

    Nov

TLRY

Tilray

$146.52

-11.62 (-7.35%)

09:56
10/17/18
10/17
09:56
10/17/18
09:56
Hot Stocks
Tilray CEO says cannabis could disrupt $150B-$200B from other markets »

Tilray CEO Brendan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISCB

Discovery Inc.

$34.00

(0.00%)

09:55
10/17/18
10/17
09:55
10/17/18
09:55
Hot Stocks
Breaking Hot Stocks news story on Discovery Inc. »

Discovery Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOP

Shopify

$138.20

-7.75 (-5.31%)

09:55
10/17/18
10/17
09:55
10/17/18
09:55
Options
Shopify put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 13

    Nov

NFLX

Netflix

$366.40

20 (5.77%)

, UAL

United Continental

$87.23

3.72 (4.45%)

09:55
10/17/18
10/17
09:55
10/17/18
09:55
Options
Early notable gainers among liquid option names on October 17th »

Notable gainers among…

NFLX

Netflix

$366.40

20 (5.77%)

UAL

United Continental

$87.23

3.72 (4.45%)

LRCX

Lam Research

$149.48

4.15 (2.86%)

GE

General Electric

$12.42

0.325 (2.69%)

AAL

American Airlines

$34.52

1.22 (3.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 25

    Oct

  • 13

    Nov

09:55
10/17/18
10/17
09:55
10/17/18
09:55
General news
FOMC minutes preview: there should be no surprises »

FOMC minutes preview:…

09:55
10/17/18
10/17
09:55
10/17/18
09:55
Conference/Events
The Brookings Institution to hold a discussion »

Unconventional Monetary…

FMS

Fresenius Medical

$40.90

-8.96 (-17.97%)

09:53
10/17/18
10/17
09:53
10/17/18
09:53
Hot Stocks
Breaking Hot Stocks news story on Fresenius Medical »

Fresenius Medical drops…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRCY

Mercury Systems

$49.91

-1.57 (-3.05%)

, SMCI

Super Micro Computer

$0.00

(0.00%)

09:51
10/17/18
10/17
09:51
10/17/18
09:51
Hot Stocks
Spruce Point links Mercury Systems to Super Micro, sees 50%-60% downside »

Citing its "forensic…

MRCY

Mercury Systems

$49.91

-1.57 (-3.05%)

SMCI

Super Micro Computer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 29

    Nov

09:49
10/17/18
10/17
09:49
10/17/18
09:49
Hot Stocks
Breaking Hot Stocks news story  »

Reading International…

PVTL

Pivotal Software

$17.82

-2.12 (-10.63%)

09:47
10/17/18
10/17
09:47
10/17/18
09:47
Hot Stocks
Pivotal Software falls -10.4% »

Pivotal Software is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMS

Fresenius Medical

$41.00

-8.86 (-17.77%)

09:47
10/17/18
10/17
09:47
10/17/18
09:47
Hot Stocks
Fresenius Medical falls -17.8% »

Fresenius Medical is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVIA

Covia

$6.78

-0.8 (-10.55%)

09:47
10/17/18
10/17
09:47
10/17/18
09:47
Hot Stocks
Covia falls -10.9% »

Covia is down -10.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRAM

Grana y Montero

$2.95

(0.00%)

09:47
10/17/18
10/17
09:47
10/17/18
09:47
Hot Stocks
Grana y Montero rises 6.6% »

Grana y Montero is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDMN

Kadmon

$3.21

0.325 (11.27%)

09:47
10/17/18
10/17
09:47
10/17/18
09:47
Hot Stocks
Kadmon rises 9.7% »

Kadmon is up 9.7%, or 28c…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WGO

Winnebago

$36.28

4.5 (14.16%)

09:47
10/17/18
10/17
09:47
10/17/18
09:47
Hot Stocks
Winnebago rises 15.5% »

Winnebago is up 15.5%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.